Kazia Therapeutics Triples Patient Enrollment in Phase 1B Breast Cancer Trial
Reported by Reuters
Sentiment
Positive
Importance
7
Price
$13.71
Mkt Cap
$154.85M
52W Low
$3.3
52W High
$17.4
Market data snapshot near publication time
Summary
Kazia Therapeutics is expanding its Phase 1B trial for Paxalisib in advanced breast cancer, increasing planned patient enrollment from 12 to 36. This significant expansion signals progress and commitment to the drug's development. For a small-cap biotech, advancing clinical trials is crucial for future valuation and pipeline strength.
At the time of this announcement, KZIA was trading at $13.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $154.8M. The 52-week trading range was $3.30 to $17.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.
Price Chart
KZIA - Latest Insights
KZIA
May 26, 2026, 8:03 AM EDT
KZIA
May 26, 2026, 8:02 AM EDT
KZIA
May 26, 2026, 8:01 AM EDT
KZIA
May 26, 2026, 8:00 AM EDT
KZIA
May 26, 2026, 7:39 AM EDT
KZIA
Apr 27, 2026, 8:30 AM EDT
KZIA
Apr 15, 2026, 8:30 AM EDT
KZIA
Apr 15, 2026, 8:00 AM EDT
KZIA
Apr 13, 2026, 5:26 PM EDT
KZIA
Apr 13, 2026, 5:25 PM EDT